Fig. 5

The landscape of the TME in HCC and the characteristics of high- or low IGS risk subgroups. A, the proportions of TME cells for 363 patients in TCGA cohort was calculated by performing CIBERSORT algorithm. Age, Gender, Grade, Stage, TP53, MUC4, TMB, OS time, and OS status were shown as patient annotations. B, the correlation of risk score with immune cells in TME. C, the proportions of TME cells in different subgroups calculated by performing ImmuCellAI. Significant statistical differences between the two subgroups were assessed using the Wilcoxon test. ns not significant, *P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001